• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Bioretec

0.02 EUR0.00 %10.7. klo 18.29
1,815 following

BRETEC

First North Finland

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
0.00 %
+1.90 %
-40.88 %
-61.19 %
-61.19 %
-86.99 %
-89.91 %
-
-91.73 %

Bioretec operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio includes, for example, implants for pediatric and adult orthopedics and other materials for bone and soft tissue injuries. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in the Nordic region.

Read more
Market cap
28.71M EUR
Turnover
10.26K EUR
P/E (adj.) (26e)
EV/EBIT (adj.) (26e)
P/B (26e)
EV/S (26e)
Dividend yield-% (26e)
Coverage
Recommendation
Accumulate
Target price
Updated
25.06.2026
Disclaimer
Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
Bioretec announces that its CEO Sarah van Hellenberg Hubar-Fisher has purchased a total of 1,660,000 shares of the company at a price of 0.02258 euros per share. She purchased the shares for a total of 37,482.20 euros. According to information published by the company at the end ...
6/4/2026, 12:00 PM
by Index
16
Stock Exchange Release Bioretec Ltd - Managers’ Transactions - Jordy Winters Bioretec Ltd Company Release 2 June 2026 at 1:25 p.m. EEST Person subject to the notification requirement Name: Jordy Winters Position: Other senior management Nature of the transaction: ACQUISITION Volume...
6/2/2026, 10:39 AM
by Index
14
Antti Siltanen has produced a comprehensive initiation report on Bioretec. These initiation reports are not behind a paywall, so this one is also available for everyone to read. Bioretec, which develops and commercializes orthopedic implants, has seen the first concrete signs of ...
6/25/2026, 7:38 AM
by Sijoittaja-alokas
13
CFO Paavola also bought a stack of shares some time ago. Quite a few insiders have been buying.
6/4/2026, 12:54 PM
by Pertti
10
He was in that role for less than 6 months, and I believe he was also let go from his previous company (Nightingale). Inside information: CFO Tuukka Paavola will not continue in the service of the company - Inderes
7/2/2026, 11:36 AM
by Roni
6
Oops, I had checked the wrong box. It should be readable now.
6/25/2026, 3:50 PM
by Antti Siltanen
4
So at least within the company, faith is strong. It’s a bit reassuring
6/5/2026, 6:42 AM
by Kahvifreak
4
Read more on our forum
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 25.06.2026

Latest extensive report

Released: 25.06.2026

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
13.8.
2026

Interim report Q2'26

12.11.
2026

Business review Q3'26

Regulatory press release07.07.2026 klo 18.55

Correction: The Board of Directors of Bioretec Ltd resolved on a new stock option plan

Bioretec
Regulatory press release02.07.2026 klo 14.30

Inside information: Chief Financial Officer Tuukka Paavola will leave the company

Bioretec
Bioretec Extensive Report: Signs of recovery in growth fracture
Extensive research25.06.2026 klo 14.13 by
Antti Siltanen

Bioretec Extensive Report: Signs of recovery in growth fracture

We expect the company to show clear signs of growth this year.

Bioretec

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Bioretec concluded change negotiations for production
Analyst Comment18.06.2026 klo 08.45 by
Antti Siltanen

Bioretec concluded change negotiations for production

The cost structure is being adjusted to reflect actual demand.

Bioretec
Press release17.06.2026 klo 16.00

Bioretec appoints Conan Cavanagh as Head of Research & Development and member of the Management Team

Bioretec
Press release17.06.2026 klo 09.00

Bioretec concludes change negotiations

Bioretec
Regulatory press release04.06.2026 klo 14.25

Bioretec Ltd - Manager's transactions - van Hellenberg Hubar-Fisher

Bioretec
Regulatory press release02.06.2026 klo 13.25

Bioretec Ltd - Manager's transactions - Jordy Winters

Bioretec
Bioretec seeks additional savings through change negotiations
Analyst Comment02.06.2026 klo 10.18 by
Antti Siltanen

Bioretec seeks additional savings through change negotiations

The company is seeking additional savings of 0.2 MEUR, as production capacity is still too high relative to demand.

Bioretec
Regulatory press release01.06.2026 klo 19.05

The Board of Directors of Bioretec Ltd resolved on a new stock option plan

Bioretec
Regulatory press release01.06.2026 klo 19.00

Inside information: Bioretec initiates new change negotiations in production to enhance operational efficiency

Bioretec
Regulatory press release18.05.2026 klo 13.45

Bioretec Ltd - Managers' transactions - Paavola

Bioretec
Bioretec Q1'26: The beginning of the year offered positive signs7:09
Video18.05.2026 klo 10.45 by
Antti Siltanen

Bioretec Q1'26: The beginning of the year offered positive signs

Bioretec's Q1 earnings positively surprised in terms of revenue and profit, particularly due to growth in the US and European markets.

Bioretec
Bioretec Q1'26: Early signs of growth emerging
Research18.05.2026 klo 10.25 by
Antti Siltanen

Bioretec Q1'26: Early signs of growth emerging

Bioretec's start to the year offered a positive surprise.

Bioretec
Regulatory press release15.05.2026 klo 09.00

Bioretec Ltd's business review Q1 2026: Early Traction from Renewed Strategy

Bioretec
Regulatory press release13.05.2026 klo 14.00

Bioretec clarifies its 2026-2028 financial target regarding the sales margin

Bioretec
Bioretec Q1'26 preview: Initiating RemeOs sales in Europe
Analyst Comment12.05.2026 klo 09.46 by
Antti Siltanen

Bioretec Q1'26 preview: Initiating RemeOs sales in Europe

In the report, our attention is drawn to the development of RemeOs sales in Europe and the United States.

Bioretec
Regulatory press release08.05.2026 klo 20.40

Bioretec Ltd's resolutions of the constitutive meeting of the Board of Directors

Bioretec
Regulatory press release08.05.2026 klo 14.45

Bioretec Ltd's resolutions of the Annual General Meeting

Bioretec
Regulatory press release29.04.2026 klo 16.40

Bioretec Ltd: Notification pursuant to Chapter 9, Section 10 of the Finnish Securities Markets Act (Sp-Rahastoyhtiö)

Bioretec